Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835919 in NASH and Type 2 Diabetes
NCT03969719Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of PF-06835919 in Nonalcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM), sponsored by Pfizer. Started Jul 2019; status: completed.
02
Drugs
PF-06835919
03
Conditions
Nonalcoholic steatohepatitis (NASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03969719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969719.